NASDAQ Framework: Cytokinetics Incorporated
Late-stage cardiovascular biopharmaceutical company 1.
1: Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF, and CK-136, a cardiac troponin activator for the potential treatment HFrEF and other types of heart failure, such as right ventricular failure resulting from impaired cardiac contractility. View Source
Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases where cardiac muscle performance is compromised 23. The company leverages its expertise in muscle biology and the mechanics of muscle performance to develop small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility 4. Cytokinetics is currently preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from pivotal Phase 3 clinical trials 5. Additionally, the company is advancing other drug candidates, including omecamtiv mecarbil and CK-586, for the treatment of various heart conditions 67.
2: Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF, and CK-136, a cardiac troponin activator for the potential treatment HFrEF and other types of heart failure, such as right ventricular failure resulting from impaired cardiac contractility. View Source3: Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to... View Source4: Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF, and CK-136, a cardiac troponin activator for the potential treatment HFrEF and other types of heart failure, such as right ventricular failure resulting from impaired cardiac contractility. View Source5: Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF, and CK-136, a cardiac troponin activator for the potential treatment HFrEF and other types of heart failure, such as right ventricular failure resulting from impaired cardiac contractility. View Source6: Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF, and CK-136, a cardiac troponin activator for the potential treatment HFrEF and other types of heart failure, such as right ventricular failure resulting from impaired cardiac contractility. View Source7: Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California. View Source
8: Insider Sale: EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK) The transaction was documented in a recent SEC Filing. Cytokinetics Inc is a biopharmaceutical company focused on the discovery and development of next-generation therapeutics for diseases characterized by impaired muscle function. The company is committed to innovative research and aims to address unmet medical needs in cardiovascular and neuromuscular diseases. GuruFocus.com • 18 hours ago Cytokinetics' Wild Ride: CEO Defends Deal That Rattled Wall Street Cytokinetics stock plummeted on a Royalty Pharma deal for three of its heart disease drugs. Here's what CEO Robert Blum says investors missed. Investor's Business Daily • 13 days ago Insider Sale: Director B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) Cytokinetics Inc is a biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Over the past year, B Parshall has engaged in multiple transactions involving the company's stock, selling a total of 15,000 shares and making no purchases. The stock of Cytokinetics Inc was trading at $54.22 on the day of the sale, giving the company a market cap of approximately $6.41 billion. GuruFocus.com • 22 days ago 7 Biotech Stocks to Boost Your Portfolio to Peak Health While innovations such as artificial intelligence have become all the rage, there’s another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if you haven’t considered the sector, it’s really time to focus on biotech stocks. First, let’s get the obvious matter out of the way: biotech stocks benefit broadly from a permanently relevant narrative. That doesn’t mean individual companies are guaranteed to rise. It’s just that the concept of addressin InvestorPlace • 27 days ago Insider Selling: Director B Parshall Sells Shares of Cytokinetics Inc (CYTK) On June 17, 2024, B Parshall, Director at Cytokinetics Inc (NASDAQ:CYTK), executed a sale of 5,000 shares of the company. GuruFocus.com • last month Insider Sale at Cytokinetics Inc (CYTK) by EVP of Research & Development Fady Malik, Executive Vice President of Research & Development at Cytokinetics Inc (NASDAQ:CYTK), sold 7,788 shares of the company on June 11, 2024. GuruFocus.com • last month Insider Sale: Director Muna Bhanji Sells Shares of Cytokinetics Inc (CYTK) On June 10, 2024, Muna Bhanji, a Director at Cytokinetics Inc (NASDAQ:CYTK), sold 2,000 shares of the company at a price of $52.07 per share. GuruFocus.com • last month Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks A study abstract shed more light on tirzepatide’s potential in MASH. Elsewhere, Cytokinetics CEO spoke on deal negotiations and AbbVie started a key multiple myeloma drug study. BioPharma Dive • last month Insider Sale: Director B Parshall Sells Shares of Cytokinetics Inc (CYTK) On June 3, 2024, B Parshall, Director at Cytokinetics Inc (NASDAQ:CYTK), executed a sale of 5,000 shares of the company. GuruFocus.com • last month Insider Sale: VP, Chief Accounting Officer Robert Wong Sells Shares of Cytokinetics Inc (CYTK) On June 3, 2024, Robert Wong, Vice President, Chief Accounting Officer of Cytokinetics Inc (NASDAQ:CYTK), executed a sale of 13,011 shares of the company. GuruFocus.com • last month Is Cytokinetics, Incorporated (NASDAQ:CYTK) the Best Mid-Cap Healthcare Stock To Buy Now? We recently compiled a list of the 7 Best Mid-Cap Healthcare Stocks To Buy Now and in this article we discuss whether Cytokinetics, Incorporated (NASDAQ:CYTK) is the best mid-cap healthcare stock to buy now according to hedge funds. Challenges in the Health Sector The healthcare industry is considered to be a fairly defensive sector due […] Insider Monkey • last month Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding. Zacks • last month Cytokinetics secures up to $575M in royalty deal, frustrating investors The biotech’s decision to give Royalty Pharma a greater share of future drug sales suggests a lower likelihood it is readying to be acquired, analysts said. BioPharma Dive • 2 months ago Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline PREMIUM MT Newswires • 2 months ago Cytokinetics Reverses Higher On 'Pristine' Results For Bristol Myers-Rivaling Heart Drug Cytokinetics said Monday its drug "significantly" improved exercise capacity in HCM patients. On Tuesday, Cytokinetics stock reversed higher. Investor's Business Daily • 2 months ago Health Care Roundup: Market Talk Read about Incyte, Cytokinetics and more in the latest Market Talks covering the Health Care sector. The Wall Street Journal • 2 months ago Cytokinetics Inc (CYTK) Reports Q1 2024 Earnings: Widening Losses Amid Expansive Clinical Trials Deep Dive into Financials and Strategic Developments GuruFocus.com • 2 months ago Cytokinetics First Quarter 2024 Earnings: Misses Expectations Cytokinetics ( NASDAQ:CYTK ) First Quarter 2024 Results Key Financial Results Net loss: US$135.6m (loss widened by 3.3... Simply Wall St. • 2 months ago Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript May 9, 2024 Cytokinetics, Incorporated isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. And welcome ladies and gentlemen to Cytokinetics First Quarter 2024 Conference Call. [Operator Instructions] I will now […] Insider Monkey • 2 months ago Cytokinetics Inc (CYTK) Q1 2024 Earnings Call Transcript Highlights: Navigating Through ... Insights into financial health, R&D progress, and strategic preparations for upcoming FDA submissions. GuruFocus.com • 2 months ago View Source9: Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF, and CK-136, a cardiac troponin activator for the potential treatment HFrEF and other types of heart failure, such as right ventricular failure resulting from impaired cardiac contractility. View Source10: Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California. View Source11: Cytokinetics Inc is a biopharmaceutical company focused on the discovery and development of next-generation therapeutics for diseases characterized by impaired muscle function. The company is committed to innovative research and aims to address unmet medical needs in cardiovascular and neuromuscular diseases. View Source12: Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function. View Source13: Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company specializes in muscle biology and the mechanics of muscle performance. It is developing small molecule drug candidates specifically engineered to... View Source
HIGH RISK
Cytokinetics Incorporated is experiencing widening losses amid expansive clinical trials, as indicated by their Q1 2024 earnings report, which showed a net loss of $135.6 million 14. Additionally, the company has been involved in multiple insider sales, with no insider purchases over the past year, which could be a red flag for potential investors 1516. The company's financial strength has been rated as low by analysts, and it has been given a "SELL" rating with a target price that has been consistently lowered over recent weeks 17. Furthermore, Cytokinetics has entered into a royalty deal that suggests a lower likelihood of being acquired, which has frustrated investors 18. All these factors combined indicate a high-risk financial situation for the company.
Cytokinetics Incorporated is experiencing widening losses amid expansive clinical trials, as indicated by their Q1 2024 earnings report, which showed a net loss of $135.6 million 14. Additionally, the company has been involved in multiple insider sales, with no insider purchases over the past year, which could be a red flag for potential investors 1516. The company's financial strength has been rated as low by analysts, and it has been given a "SELL" rating with a target price that has been consistently lowered over recent weeks 17. Furthermore, Cytokinetics has entered into a royalty deal that suggests a lower likelihood of being acquired, which has frustrated investors 18. All these factors combined indicate a high-risk financial situation for the company.
14: Insider Sale: EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK) The transaction was documented in a recent SEC Filing. Cytokinetics Inc is a biopharmaceutical company focused on the discovery and development of next-generation therapeutics for diseases characterized by impaired muscle function. The company is committed to innovative research and aims to address unmet medical needs in cardiovascular and neuromuscular diseases. GuruFocus.com • 18 hours ago Cytokinetics' Wild Ride: CEO Defends Deal That Rattled Wall Street Cytokinetics stock plummeted on a Royalty Pharma deal for three of its heart disease drugs. Here's what CEO Robert Blum says investors missed. Investor's Business Daily • 13 days ago Insider Sale: Director B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) Cytokinetics Inc is a biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Over the past year, B Parshall has engaged in multiple transactions involving the company's stock, selling a total of 15,000 shares and making no purchases. The stock of Cytokinetics Inc was trading at $54.22 on the day of the sale, giving the company a market cap of approximately $6.41 billion. GuruFocus.com • 22 days ago 7 Biotech Stocks to Boost Your Portfolio to Peak Health While innovations such as artificial intelligence have become all the rage, there’s another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if you haven’t considered the sector, it’s really time to focus on biotech stocks. First, let’s get the obvious matter out of the way: biotech stocks benefit broadly from a permanently relevant narrative. That doesn’t mean individual companies are guaranteed to rise. It’s just that the concept of addressin InvestorPlace • 27 days ago Insider Selling: Director B Parshall Sells Shares of Cytokinetics Inc (CYTK) On June 17, 2024, B Parshall, Director at Cytokinetics Inc (NASDAQ:CYTK), executed a sale of 5,000 shares of the company. GuruFocus.com • last month Insider Sale at Cytokinetics Inc (CYTK) by EVP of Research & Development Fady Malik, Executive Vice President of Research & Development at Cytokinetics Inc (NASDAQ:CYTK), sold 7,788 shares of the company on June 11, 2024. GuruFocus.com • last month Insider Sale: Director Muna Bhanji Sells Shares of Cytokinetics Inc (CYTK) On June 10, 2024, Muna Bhanji, a Director at Cytokinetics Inc (NASDAQ:CYTK), sold 2,000 shares of the company at a price of $52.07 per share. GuruFocus.com • last month Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks A study abstract shed more light on tirzepatide’s potential in MASH. Elsewhere, Cytokinetics CEO spoke on deal negotiations and AbbVie started a key multiple myeloma drug study. BioPharma Dive • last month Insider Sale: Director B Parshall Sells Shares of Cytokinetics Inc (CYTK) On June 3, 2024, B Parshall, Director at Cytokinetics Inc (NASDAQ:CYTK), executed a sale of 5,000 shares of the company. GuruFocus.com • last month Insider Sale: VP, Chief Accounting Officer Robert Wong Sells Shares of Cytokinetics Inc (CYTK) On June 3, 2024, Robert Wong, Vice President, Chief Accounting Officer of Cytokinetics Inc (NASDAQ:CYTK), executed a sale of 13,011 shares of the company. GuruFocus.com • last month Is Cytokinetics, Incorporated (NASDAQ:CYTK) the Best Mid-Cap Healthcare Stock To Buy Now? We recently compiled a list of the 7 Best Mid-Cap Healthcare Stocks To Buy Now and in this article we discuss whether Cytokinetics, Incorporated (NASDAQ:CYTK) is the best mid-cap healthcare stock to buy now according to hedge funds. Challenges in the Health Sector The healthcare industry is considered to be a fairly defensive sector due […] Insider Monkey • last month Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding. Zacks • last month Cytokinetics secures up to $575M in royalty deal, frustrating investors The biotech’s decision to give Royalty Pharma a greater share of future drug sales suggests a lower likelihood it is readying to be acquired, analysts said. BioPharma Dive • 2 months ago Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline PREMIUM MT Newswires • 2 months ago Cytokinetics Reverses Higher On 'Pristine' Results For Bristol Myers-Rivaling Heart Drug Cytokinetics said Monday its drug "significantly" improved exercise capacity in HCM patients. On Tuesday, Cytokinetics stock reversed higher. Investor's Business Daily • 2 months ago Health Care Roundup: Market Talk Read about Incyte, Cytokinetics and more in the latest Market Talks covering the Health Care sector. The Wall Street Journal • 2 months ago Cytokinetics Inc (CYTK) Reports Q1 2024 Earnings: Widening Losses Amid Expansive Clinical Trials Deep Dive into Financials and Strategic Developments GuruFocus.com • 2 months ago Cytokinetics First Quarter 2024 Earnings: Misses Expectations Cytokinetics ( NASDAQ:CYTK ) First Quarter 2024 Results Key Financial Results Net loss: US$135.6m (loss widened by 3.3... Simply Wall St. • 2 months ago Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript May 9, 2024 Cytokinetics, Incorporated isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. And welcome ladies and gentlemen to Cytokinetics First Quarter 2024 Conference Call. [Operator Instructions] I will now […] Insider Monkey • 2 months ago Cytokinetics Inc (CYTK) Q1 2024 Earnings Call Transcript Highlights: Navigating Through ... Insights into financial health, R&D progress, and strategic preparations for upcoming FDA submissions. GuruFocus.com • 2 months ago View Source15: Insider Sale: EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK) The transaction was documented in a recent SEC Filing. Cytokinetics Inc is a biopharmaceutical company focused on the discovery and development of next-generation therapeutics for diseases characterized by impaired muscle function. The company is committed to innovative research and aims to address unmet medical needs in cardiovascular and neuromuscular diseases. GuruFocus.com • 18 hours ago Cytokinetics' Wild Ride: CEO Defends Deal That Rattled Wall Street Cytokinetics stock plummeted on a Royalty Pharma deal for three of its heart disease drugs. Here's what CEO Robert Blum says investors missed. Investor's Business Daily • 13 days ago Insider Sale: Director B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) Cytokinetics Inc is a biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Over the past year, B Parshall has engaged in multiple transactions involving the company's stock, selling a total of 15,000 shares and making no purchases. The stock of Cytokinetics Inc was trading at $54.22 on the day of the sale, giving the company a market cap of approximately $6.41 billion. GuruFocus.com • 22 days ago 7 Biotech Stocks to Boost Your Portfolio to Peak Health While innovations such as artificial intelligence have become all the rage, there’s another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if you haven’t considered the sector, it’s really time to focus on biotech stocks. First, let’s get the obvious matter out of the way: biotech stocks benefit broadly from a permanently relevant narrative. That doesn’t mean individual companies are guaranteed to rise. It’s just that the concept of addressin InvestorPlace • 27 days ago Insider Selling: Director B Parshall Sells Shares of Cytokinetics Inc (CYTK) On June 17, 2024, B Parshall, Director at Cytokinetics Inc (NASDAQ:CYTK), executed a sale of 5,000 shares of the company. GuruFocus.com • last month Insider Sale at Cytokinetics Inc (CYTK) by EVP of Research & Development Fady Malik, Executive Vice President of Research & Development at Cytokinetics Inc (NASDAQ:CYTK), sold 7,788 shares of the company on June 11, 2024. GuruFocus.com • last month Insider Sale: Director Muna Bhanji Sells Shares of Cytokinetics Inc (CYTK) On June 10, 2024, Muna Bhanji, a Director at Cytokinetics Inc (NASDAQ:CYTK), sold 2,000 shares of the company at a price of $52.07 per share. GuruFocus.com • last month Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks A study abstract shed more light on tirzepatide’s potential in MASH. Elsewhere, Cytokinetics CEO spoke on deal negotiations and AbbVie started a key multiple myeloma drug study. BioPharma Dive • last month Insider Sale: Director B Parshall Sells Shares of Cytokinetics Inc (CYTK) On June 3, 2024, B Parshall, Director at Cytokinetics Inc (NASDAQ:CYTK), executed a sale of 5,000 shares of the company. GuruFocus.com • last month Insider Sale: VP, Chief Accounting Officer Robert Wong Sells Shares of Cytokinetics Inc (CYTK) On June 3, 2024, Robert Wong, Vice President, Chief Accounting Officer of Cytokinetics Inc (NASDAQ:CYTK), executed a sale of 13,011 shares of the company. GuruFocus.com • last month Is Cytokinetics, Incorporated (NASDAQ:CYTK) the Best Mid-Cap Healthcare Stock To Buy Now? We recently compiled a list of the 7 Best Mid-Cap Healthcare Stocks To Buy Now and in this article we discuss whether Cytokinetics, Incorporated (NASDAQ:CYTK) is the best mid-cap healthcare stock to buy now according to hedge funds. Challenges in the Health Sector The healthcare industry is considered to be a fairly defensive sector due […] Insider Monkey • last month Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding. Zacks • last month Cytokinetics secures up to $575M in royalty deal, frustrating investors The biotech’s decision to give Royalty Pharma a greater share of future drug sales suggests a lower likelihood it is readying to be acquired, analysts said. BioPharma Dive • 2 months ago Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline PREMIUM MT Newswires • 2 months ago Cytokinetics Reverses Higher On 'Pristine' Results For Bristol Myers-Rivaling Heart Drug Cytokinetics said Monday its drug "significantly" improved exercise capacity in HCM patients. On Tuesday, Cytokinetics stock reversed higher. Investor's Business Daily • 2 months ago Health Care Roundup: Market Talk Read about Incyte, Cytokinetics and more in the latest Market Talks covering the Health Care sector. The Wall Street Journal • 2 months ago Cytokinetics Inc (CYTK) Reports Q1 2024 Earnings: Widening Losses Amid Expansive Clinical Trials Deep Dive into Financials and Strategic Developments GuruFocus.com • 2 months ago Cytokinetics First Quarter 2024 Earnings: Misses Expectations Cytokinetics ( NASDAQ:CYTK ) First Quarter 2024 Results Key Financial Results Net loss: US$135.6m (loss widened by 3.3... Simply Wall St. • 2 months ago Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript May 9, 2024 Cytokinetics, Incorporated isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. And welcome ladies and gentlemen to Cytokinetics First Quarter 2024 Conference Call. [Operator Instructions] I will now […] Insider Monkey • 2 months ago Cytokinetics Inc (CYTK) Q1 2024 Earnings Call Transcript Highlights: Navigating Through ... Insights into financial health, R&D progress, and strategic preparations for upcoming FDA submissions. GuruFocus.com • 2 months ago View Source16: Over the past year, Fady Malik has sold a total of 136,123 shares and has not made any purchases of the company's stock. The insider transaction history for Cytokinetics Inc shows a total of 43 insider sells and no insider buys over the same timeframe. View Source17: Raising target price to $45.00 CYTOKINETICS INC has an Investment Rating of SELL; a target price of $45.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium. Rating Price Target Argus• 7 days ago Lowering target price to $44.00 CYTOKINETICS INC has an Investment Rating of SELL; a target price of $44.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium. Rating Price Target Argus• 14 days ago Rating decreased to a SELL CYTOKINETICS INC has an Investment Rating of SELL; a target price of $58.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Medium. Rating Price Target Argus• 21 days ago Raising target price to $56.00 CYTOKINETICS INC has an Investment Rating of HOLD; a target price of $56.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium. Rating Price Target Argus• 28 days ago View Source18: Insider Sale: EVP Research & Development Fady Malik Sells Shares of Cytokinetics Inc (CYTK) The transaction was documented in a recent SEC Filing. Cytokinetics Inc is a biopharmaceutical company focused on the discovery and development of next-generation therapeutics for diseases characterized by impaired muscle function. The company is committed to innovative research and aims to address unmet medical needs in cardiovascular and neuromuscular diseases. GuruFocus.com • 18 hours ago Cytokinetics' Wild Ride: CEO Defends Deal That Rattled Wall Street Cytokinetics stock plummeted on a Royalty Pharma deal for three of its heart disease drugs. Here's what CEO Robert Blum says investors missed. Investor's Business Daily • 13 days ago Insider Sale: Director B Parshall Sells 5,000 Shares of Cytokinetics Inc (CYTK) Cytokinetics Inc is a biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Over the past year, B Parshall has engaged in multiple transactions involving the company's stock, selling a total of 15,000 shares and making no purchases. The stock of Cytokinetics Inc was trading at $54.22 on the day of the sale, giving the company a market cap of approximately $6.41 billion. GuruFocus.com • 22 days ago 7 Biotech Stocks to Boost Your Portfolio to Peak Health While innovations such as artificial intelligence have become all the rage, there’s another type of technology – biotechnology – that deserves careful consideration for your portfolio. Indeed, if you haven’t considered the sector, it’s really time to focus on biotech stocks. First, let’s get the obvious matter out of the way: biotech stocks benefit broadly from a permanently relevant narrative. That doesn’t mean individual companies are guaranteed to rise. It’s just that the concept of addressin InvestorPlace • 27 days ago Insider Selling: Director B Parshall Sells Shares of Cytokinetics Inc (CYTK) On June 17, 2024, B Parshall, Director at Cytokinetics Inc (NASDAQ:CYTK), executed a sale of 5,000 shares of the company. GuruFocus.com • last month Insider Sale at Cytokinetics Inc (CYTK) by EVP of Research & Development Fady Malik, Executive Vice President of Research & Development at Cytokinetics Inc (NASDAQ:CYTK), sold 7,788 shares of the company on June 11, 2024. GuruFocus.com • last month Insider Sale: Director Muna Bhanji Sells Shares of Cytokinetics Inc (CYTK) On June 10, 2024, Muna Bhanji, a Director at Cytokinetics Inc (NASDAQ:CYTK), sold 2,000 shares of the company at a price of $52.07 per share. GuruFocus.com • last month Lilly details MASH data for tirzepatide; Cytokinetics comments on past sale talks A study abstract shed more light on tirzepatide’s potential in MASH. Elsewhere, Cytokinetics CEO spoke on deal negotiations and AbbVie started a key multiple myeloma drug study. BioPharma Dive • last month Insider Sale: Director B Parshall Sells Shares of Cytokinetics Inc (CYTK) On June 3, 2024, B Parshall, Director at Cytokinetics Inc (NASDAQ:CYTK), executed a sale of 5,000 shares of the company. GuruFocus.com • last month Insider Sale: VP, Chief Accounting Officer Robert Wong Sells Shares of Cytokinetics Inc (CYTK) On June 3, 2024, Robert Wong, Vice President, Chief Accounting Officer of Cytokinetics Inc (NASDAQ:CYTK), executed a sale of 13,011 shares of the company. GuruFocus.com • last month Is Cytokinetics, Incorporated (NASDAQ:CYTK) the Best Mid-Cap Healthcare Stock To Buy Now? We recently compiled a list of the 7 Best Mid-Cap Healthcare Stocks To Buy Now and in this article we discuss whether Cytokinetics, Incorporated (NASDAQ:CYTK) is the best mid-cap healthcare stock to buy now according to hedge funds. Challenges in the Health Sector The healthcare industry is considered to be a fairly defensive sector due […] Insider Monkey • last month Why Cytokinetics (CYTK) Stock Price Was Down 17% on Thursday Cytokinetics (CYTK) declines after announcing plans for raising about a billion dollars in funding. Zacks • last month Cytokinetics secures up to $575M in royalty deal, frustrating investors The biotech’s decision to give Royalty Pharma a greater share of future drug sales suggests a lower likelihood it is readying to be acquired, analysts said. BioPharma Dive • 2 months ago Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline Cytokinetics, Royalty Pharma Unveil up to $575 Million Funding to Advance Research Pipeline PREMIUM MT Newswires • 2 months ago Cytokinetics Reverses Higher On 'Pristine' Results For Bristol Myers-Rivaling Heart Drug Cytokinetics said Monday its drug "significantly" improved exercise capacity in HCM patients. On Tuesday, Cytokinetics stock reversed higher. Investor's Business Daily • 2 months ago Health Care Roundup: Market Talk Read about Incyte, Cytokinetics and more in the latest Market Talks covering the Health Care sector. The Wall Street Journal • 2 months ago Cytokinetics Inc (CYTK) Reports Q1 2024 Earnings: Widening Losses Amid Expansive Clinical Trials Deep Dive into Financials and Strategic Developments GuruFocus.com • 2 months ago Cytokinetics First Quarter 2024 Earnings: Misses Expectations Cytokinetics ( NASDAQ:CYTK ) First Quarter 2024 Results Key Financial Results Net loss: US$135.6m (loss widened by 3.3... Simply Wall St. • 2 months ago Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript Cytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call Transcript May 9, 2024 Cytokinetics, Incorporated isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon. And welcome ladies and gentlemen to Cytokinetics First Quarter 2024 Conference Call. [Operator Instructions] I will now […] Insider Monkey • 2 months ago Cytokinetics Inc (CYTK) Q1 2024 Earnings Call Transcript Highlights: Navigating Through ... Insights into financial health, R&D progress, and strategic preparations for upcoming FDA submissions. GuruFocus.com • 2 months ago View Source
YES
Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from pivotal Phase 3 clinical trials 19. Additionally, the company is advancing other drug candidates, including omecamtiv mecarbil and CK-586, for the treatment of various heart conditions 20.
Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from pivotal Phase 3 clinical trials 19. Additionally, the company is advancing other drug candidates, including omecamtiv mecarbil and CK-586, for the treatment of various heart conditions 20.
19: Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF, and CK-136, a cardiac troponin activator for the potential treatment HFrEF and other types of heart failure, such as right ventricular failure resulting from impaired cardiac contractility. View Source20: Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF, and CK-136, a cardiac troponin activator for the potential treatment HFrEF and other types of heart failure, such as right ventricular failure resulting from impaired cardiac contractility. View Source
Cytokinetics Incorporated's product roadmap for 2024 through 2026 focuses on advancing its pipeline of muscle activators and inhibitors, particularly targeting cardiovascular diseases. The company is preparing for regulatory submissions for aficamten, a next-in-class cardiac myosin inhibitor, following successful Phase 3 clinical trials 21. Additionally, Cytokinetics is progressing with other drug candidates such as omecamtiv mecarbil, a cardiac muscle activator for heart failure, and CK-586, a cardiac myosin inhibitor for HFpEF 22. The company is also conducting multiple Phase 3 trials for aficamten in various patient populations, including those with obstructive and non-obstructive hypertrophic cardiomyopathy (HCM) 23.
21: Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF, and CK-136, a cardiac troponin activator for the potential treatment HFrEF and other types of heart failure, such as right ventricular failure resulting from impaired cardiac contractility. View Source22: Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF, and CK-136, a cardiac troponin activator for the potential treatment HFrEF and other types of heart failure, such as right ventricular failure resulting from impaired cardiac contractility. View Source23: Cytokinetics is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact myocardial muscle function and contractility. Cytokinetics is preparing for regulatory submissions for aficamten, its next-in-class cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in obstructive hypertrophic cardiomyopathy. Aficamten is also currently being evaluated in MAPLE-HCM, a Phase 3 clinical trial of aficamten as monotherapy compared to metoprolol as monotherapy in patients with obstructive HCM, ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM, CEDAR-HCM, a clinical trial of aficamten in a pediatric population with obstructive HCM, and FOREST-HCM, an open-label extension clinical study of aficamten in patients with HCM. Cytokinetics is also developing omecamtiv mecarbil, a cardiac muscle activator, in patients with heart failure. Additionally, Cytokinetics is developing CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from aficamten for the potential treatment of HFpEF, and CK-136, a cardiac troponin activator for the potential treatment HFrEF and other types of heart failure, such as right ventricular failure resulting from impaired cardiac contractility. View Source